James Kenney, MD
Family Medicine · Henderson, NCNPI 1639177249
Payments from drug & device makers
Across 206 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$612
- Preventric Diagnostics, Inc.$352
- AstraZeneca$290
- Pfizer$279
- Sunovion Pharmaceuticals Inc.$264
- Novartis$220
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,50699%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $612 |
| Preventric Diagnostics, Inc. | 2 | $352 |
| AstraZeneca | 21 | $290 |
| Pfizer | 24 | $279 |
| Sunovion Pharmaceuticals Inc. | 16 | $264 |
| Novartis | 13 | $220 |
| Johnson & Johnson | 14 | $204 |
| Lilly USA, LLC | 12 | $202 |
| Novo Nordisk | 10 | $159 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Global Blood Therapeutics, Inc. | 4 | $64 |
| Abbott | 3 | $59 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Exact Sciences | 3 | $57 |
| SK Life Science, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| UCB, Inc. | 2 | $48 |
| Merck | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| AbbVie | 2 | $38 |
| Amgen | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Lifescan, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $34 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $28 |
| Ardelyx, Inc. | 1 | $27 |
| Medtronic | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| CMP Pharma, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,541 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 759 | $267,722 |
| JardianceEmpagliflozin | 194 | $117,039 |
| OzempicSemaglutide | 114 | $115,983 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $82,331 |
| JanuviaSitagliptin Phosphate | 77 | $70,528 |
| FarxigaDapagliflozin Propanediol | 98 | $69,506 |
| XareltoRivaroxaban | 126 | $68,478 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $37,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $34,524 |
| LinzessLinaclotide | 38 | $27,896 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $25,752 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $22,297 |
| Atorvastatin Calcium | 1,369 | $21,119 |
| TivicayDolutegravir Sodium | 18 | $20,096 |
| ProcritEpoetin Alfa | 18 | $19,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $279 | $274,003779 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $126,408212 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $290 | $126,327220 claims |
| Novo NordiskOzempic | $159 | $115,983114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $612 | $108,083169 claims |
| MerckJanuvia, Janumet | $46 | $107,860114 claims |
| Johnson & JohnsonXarelto, Procrit | $204 | $87,524144 claims |
| AbbVieLinzess | $38 | $27,89638 claims |
| Lilly USA, LLCMounjaro | $202 | $11,17711 claims |
| NovartisEntresto | $220 | $10,85019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Henderson
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.